Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 2.5 mg/6.25 mg, packaged as (a) 30-coun...

FDA Drug Recall #D-0199-2026 - Class III, November 21, 2025

Recall Summary

Recall Number D-0199-2026
Classification Class III, Low risk
Date Initiated November 21, 2025
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Glenmark Pharmaceuticals Inc., USA
Location Elmwood Park, NJ
Product Type Drugs
Quantity 11,136 bottles

Product Description

Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 2.5 mg/6.25 mg, packaged as (a) 30-count bottles, NDC-68462-878-30; (b) 100-count bottle, NDC-68462-878-01; (c) 500-count bottles, NDC-68462-878-05; Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, Inda. Manufactured for: Glenmark Pharmaceuticals, Inc., USA, Mahwah, NJ 07430.

Reason for Recall

Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe

Distribution Pattern

Nationwide in the USA

Lot / Code Information

Lot #: (a): Lot 17232401, exp 11/2025; Lot 17240974, exp 05/2026 (b): Lot 17232401, exp 11/2025; Lot 17240974, exp 05/2026 (c): Lot 17232401, exp 11/2025; Lot 17240974, exp 05/2026

Other Recalls from Glenmark Pharmaceuticals Inc., USA

Recall # Classification Product Date
D-0731-2026 Class II Azelaic Acid Gel, 15%, 50 gram tubes, For Topic... Jul 23, 2026
D-0588-2026 Class II Alyacen 7/7/7, Norethindrone and Ethinyl Estrad... May 27, 2026
D-0246-2026 Class II Ondansetron Orally Disintegrating Tablets, USP,... Dec 30, 2025
D-0222-2026 Class III Nebivolol Tablets, 20 mg, 90 Tablets, Rx Only, ... Nov 18, 2025
D-0662-2025 Class II Azelaic Acid Gel, 15%, 50 grams, For Topical Us... Sep 17, 2025

Frequently Asked Questions

Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections, all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.